Moderna

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

Retrieved on: 
Tuesday, September 27, 2022
Health, Pharmaceutical, Trustee, Health, Wendell Pritchett, Goldman, Efficiency, Director, NYSE, Third Rock Ventures, LLC, AmerisourceBergen, American Red Cross, Flare, Norwest Venture Partners, Growth, Biotechnology, Wharton School of the University of Pennsylvania, Pharmacy, Cowen Inc., Moderna, Therapy, Harvard University, Solution, Board of directors, ABC, Board, University, David Berry (inventor), Holding company, Management

AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022.

Key Points: 
  • AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022.
  • With the election of Dr. Kim, the Board of Directors will increase from ten to eleven members, nine of whom are independent.
  • We look forward to Dr. Kim joining AmerisourceBergens Board of Directors.
  • His business acumen, deep financial expertise, and healthcare knowledge will bring great perspective to the Board, AmerisourceBergen, and our stakeholders, said Jane E. Henney, M.D., Lead Independent Director.

NCCN Updates Recommendations for COVID-19 Vaccination with Information on Bivalent Vaccines, Children with Cancer, and Other Developments

Retrieved on: 
Thursday, September 22, 2022
Adult, Decision-making, Ann, COVID-19, Lymphatic system, Policy, Twitter, Malignancy, Risk, RNA transfection, Pre-exposure prophylaxis, Hospital, Vaccination, Health, CAR, Immunity, Immunotherapy, Patient, Cancer, Myocarditis, Adolescence, Vaccine, Immunodeficiency, National Comprehensive Cancer Network, Omicron, Vaccine hesitancy, Caregiver, Journal of the National Comprehensive Cancer Network, Infection, Research, Medicine, Awareness, Immune system, Education, Lurie Children's Hospital, NCCN, Co-leader of the Scottish Green Party, Pharmaceutical industry, Medical device, MD, Moderna, Northwestern Medicine, Pfizer

PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—released updated recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. This latest evidence-based, expert consensus-formulated summary on cancer and COVID-19 vaccination and prevention is available for free at NCCN.org/covid-19. Significant revisions include new recommendations for the recently-approved bivalent vaccines and advice on protecting children with cancer.

Key Points: 
  • This latest evidence-based, expert consensus-formulated summary on cancer and COVID-19 vaccination and prevention is available for free at NCCN.org/covid-19 .
  • Significant revisions include new recommendations for the recently-approved bivalent vaccines and advice on protecting children with cancer.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .
  • Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg , Instagram @NCCNorg , and Twitter @NCCN .

Regeneron Co-Founder and Former Moderna Chief Medical Officer Among Healthcare Innovators to Speak at Klick Ideas Exchange

Retrieved on: 
Tuesday, September 20, 2022
Other Health, General Health, Internet, Technology, Other Communications, Public Relations, Investor Relations, Science, Marketing, Advertising, Communications, Other Technology, Health, Other Science, Sensei, Health, Inclusion, United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, 100 Best Workplaces in Europe, Twitter, Health equity, Patient, Millennials, Science, Ecosystem, Click, Medicine, Management, Pharmaceutical industry, Moderna, Woman, Paulo

We are proud to mark the return of Klick Ideas Exchange with some of the most prolific and brilliant scientists and thinkers of our time, said Klick Co-Founder and Chairman Leerom Segal.

Key Points: 
  • We are proud to mark the return of Klick Ideas Exchange with some of the most prolific and brilliant scientists and thinkers of our time, said Klick Co-Founder and Chairman Leerom Segal.
  • The contributions they have made to world health are immeasurable and they continue to serve as an inspiration to us all.
  • Klick Ideas Exchange will cover a variety of important health-focused topics, including the next frontiers of science, personalizing blockbuster medicines for patients, health equity, and whats now, near, and next in health and biomedicine.
  • The Klick Group of companiesKlick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labsis an ecosystem of brilliant talent collectively working to maximize their people and clients full potential.

Anima Research Center participating in a trial for an investigational RSV vaccine   

Retrieved on: 
Thursday, September 15, 2022
Central nervous system disease, Respiratory syncytial virus, Virus, RSV, Pneumonia, CEO, Vaccine, Anima, Family, Doctor of Philosophy, CNS, Research, Principal investigator, Death, Pharmaceutical industry, Moderna

There are currently no approved vaccines or treatments for RSV, and Anima recently partnered with US biotech company Moderna to evaluate an investigational RSV vaccine, aimed at the over 60s.

Key Points: 
  • There are currently no approved vaccines or treatments for RSV, and Anima recently partnered with US biotech company Moderna to evaluate an investigational RSV vaccine, aimed at the over 60s.
  • Anima Research Center is the largest clinical trial center in Belgium.
  • Despite huge amounts of research a vaccine has so far eluded developers, but were pleased to be supporting Moderna to recruit for their trial to evaluate an investigational vaccine.
  • To read more about the trial and check your eligibility, visit the Anima Research website: https://www.animaresearch.com/en/study/respiratoir-syncytieel-virus-rsv/

Albertsons Companies Invests in Community Health with Pharmacy Enhancements to Support Comprehensive Immunization Access

Retrieved on: 
Monday, September 12, 2022
COVID-19, Infectious Diseases, Supermarket, Hispanic, Food, Beverage, General Health, Consumer, Health, Retail, Organic Food, Adult, Albertsons, Food Lover's Market, Medicare Part D, Thumb, Center, COVID-19, Shaw's and Star Market, Medicare, FDA, Centers for Disease Control and Prevention, Organization, Jewel (supermarket), Company, Kings Food Markets, Pharmacy, Investor, HHS, Star Market, Immunization, Patient, Investment, Federation, Tetanus, District, Pharmacist, Pneumonia, Technology, Safeway, Vaccine, Student, CDC, Nursing, Food, Randalls, Insurance, HPV, Shingles, Pavilion, School, Haggen, EVP, Acme, Pfizer, Chief digital officer, Pharmaceutical industry, Moderna, Health, United Supermarkets

Albertsons Companies today announced investments in technology, vaccine inventory and patient services to increase immunization access and personalized care at more than 1,700 pharmacy locations.

Key Points: 
  • Albertsons Companies today announced investments in technology, vaccine inventory and patient services to increase immunization access and personalized care at more than 1,700 pharmacy locations.
  • Pharmacy enhancements and incentives include:
    Flu season: The Quadrivalent flu vaccine, Flublok and Fluzone HD are available.
  • COVID-19 bivalent vaccines: The reformulated boosters from Moderna and Pfizer-BioNTech target both the original virus and omicron variants BA.4 and BA.5.
  • Providers can check the HHS COVID-19 Therapeutics Locator to locate an Albertsons pharmacy carrying Evusheld.

Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, RNA interference, Security (finance), Engineering, RNA, Immunomodulation, UC, Cancer, Research, ARCH, Degenerative disease, Therapy, Genetics, Gene editing, Vaccine, Regenerative medicine, Hematology, Max Planck Institute of Immunobiology and Epigenetics, Global health, Tissue, Molecular medicine, Infection, Science, Half-life, Lists of diseases, U.S. Securities and Exchange Commission, Data science, Disease, MBA, University of California, San Diego, Alnylam Pharmaceuticals, Medicine, Coronavirus Scientific Advisory Board (Turkey), Â, Stanford University, Max Planck Society, Orbital, RNA transfection, Moderna, Private Securities Litigation Reform Act, Automation, Growth, Cell Transplantation, Health, Drug development, Patient, Pharmaceutical industry, Management, Risk management, Biotechnology, Beam

Orbital Therapeutics has a unique opportunity to integrate and apply a spectrum of innovative RNA technologies to advance a portfolio that could dramatically expand the potential of todays RNA therapeutic approaches.

Key Points: 
  • Orbital Therapeutics has a unique opportunity to integrate and apply a spectrum of innovative RNA technologies to advance a portfolio that could dramatically expand the potential of todays RNA therapeutic approaches.
  • First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA and complications associated with immunogenicity.
  • As the company grows, Orbital intends to continue investing in the growth of its platform capabilities and technologies.
  • The field of RNA medicines is advancing rapidly, and we are excited to participate in the launch of Orbital.

Scheduling for COVID-19 Boosters Now Available at Rite Aid and Bartell Drugs Locations

Retrieved on: 
Tuesday, September 6, 2022
Retail, Pharmaceutical, Women, Infectious Diseases, Seniors, Convenience Store, Teens, Discount, Variety, Children, Men, Specialty, Family, Consumer, Health, Medical Supplies, Pharmacist, COVID-19, NYSE, Vaccination, Vaccine, Pfizer, Disease management, Rite Aid, Pacific Northwest, Bartell Drugs, RAD, Pharmacy, Industry, Health, COVID, Aid, Omicron, Travel, Elixir, Moderna

Rite Aid (NYSE: RAD) today announced that scheduling is now available for the updated boosters of the mRNA Pfizer and Moderna COVID-19 vaccines at its locations and at Bartell Drugs locations in the Pacific Northwest.

Key Points: 
  • Rite Aid (NYSE: RAD) today announced that scheduling is now available for the updated boosters of the mRNA Pfizer and Moderna COVID-19 vaccines at its locations and at Bartell Drugs locations in the Pacific Northwest.
  • Rite Aid encourages customers to get their flu shots at the same time they receive their latest COVID-19 vaccination.
  • Customers may receive their updated booster dose at Rite Aid or Bartell Drugs regardless of where they received their primary series or previous booster(s).
  • Rite Aid employs more than 6,400 pharmacists and operates more than 2,350 retail pharmacy locations across 17 states.

Seasonal Flu Vaccinations Now Available at Giant Food Pharmacies as DMV Preps for Back-to-School Season

Retrieved on: 
Thursday, September 1, 2022
Supermarket, Starbucks, Partnership, Pharmacist, PNC Bank Arts Center, COVID-19, Research, CEO, Immunization, Program, Vaccination, Ageing, Food, View, Insurance, Vaccine, Pfizer, Pharmacy, Airstream, Anxiety, Giant Food, Social equality, Neighbor, Multimedia, Fear, Medicare, Health, Child, Travel, Pharmaceutical industry, Giant, Hope, Moderna

LANDOVER, Md. , Sept. 1, 2022 /PRNewswire/ -- Giant Food, the leading greater Washington D.C. regional grocery chain, today announces that seasonal flu vaccinations are once again available at all 153 in-store pharmacies for both adults and children*. The vaccinations are administered by Giant's certified in-store pharmacists, require no appointment, and are often covered in-full by most insurance plans.

Key Points: 
  • Customers can find the Super Rewards 'game boards' at Giant pharmacies by asking the pharmacy team.
  • Giant is also currently administering pediatric COVID-19 vaccinations of either Pfizer-BioNTech or Moderna for children 3 years of age and older at select pharmacies .
  • To help customers stay healthy throughout the flu season, Giant has made getting vaccinations simple and easy with no appointment needed.
  • The flu vaccines offered this season will cover four strains of the flu virus and Giant will again offer high-dose flu vaccines for adults aged 65 and older.

ISPE Announces 2022-2023 International Board of Directors Election Results

Retrieved on: 
Wednesday, August 31, 2022
AstraZeneca, CEO, PE, NORTH, International Board, Foreign policy, Doctor of Philosophy, Solution, ISPE, International Society, Board, CRB, Computer, National Science Board, Syneos Health, Pfizer, Association, Compliance, Medication, Society, Internet service provider, Management, Audit, Moderna

NORTH BETHESDA, Md. , Aug. 31, 2022   /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is pleased to announce the results of its 2022–2023 International Board of Directors election. The election was run by an independent third party, Intelliscan, Inc., who provided ISPE with the final audited results.

Key Points: 
  • ISPE is pleased to announce the results of its 20222023 International Board of Directors election.
  • The election was run by an independent third party, Intelliscan, Inc., who provided ISPE with the final audited results.
  • NORTH BETHESDA, Md., Aug. 31, 2022 /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is pleased to announce the results of its 20222023 International Board of Directors election.
  • Explore the ISPE Board of Directors Election webpage for complete biographical information on all of ISPE's International Board.

DGAP-News: Moderna, Inc.: Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Retrieved on: 
Monday, August 29, 2022
Public health, Science, RNA, Safety, Ageing, Degenerative disease, Government, NASDAQ, Vaccine, Risk, Infection, U.S. Securities and Exchange Commission, SEC, MRNA, Severe acute respiratory syndrome coronavirus 2, MA, Intention, GMT, Leadership, Company, Biotechnology, Therapy, Compugen (Israeli company), RNA transfection, Clinical trial, Annual report, Private Securities Litigation Reform Act, Compte rendu, COVID-19, Swissmedic, Moderna, Omicron

Moderna, Inc.: Swissmedic Authorizes Modernas Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Key Points: 
  • Moderna, Inc.: Swissmedic Authorizes Modernas Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
    The issuer is solely responsible for the content of this announcement.
  • Swissmedic Authorizes Modernas Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
    CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic has granted temporary authorization for the use of Moderna's Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron (mRNA-1273.214) for active immunization to prevent SARS-CoV-2 virus-induced Coronavirus-2019 disease for individuals aged 18 years and older.
  • "We are delighted to receive authorization from Swissmedic for our next-generation bivalent vaccine, mRNA-1273.214.
  • A booster dose of Spikevax Bivalent Original/Omicron (mRNA-1273.214) increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels.